Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
The Pharma Data
SEPTEMBER 29, 2021
Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee. “If
Let's personalize your content